Using AI to improve treatment for head and neck cancer
Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence: an International Cohort Study of Electronic Health Records. HNC-TACTIC.
This study is testing if using AI to analyze health records can help doctors find out which head and neck cancer patients are at risk of their cancer coming back and who might do better with immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Savana Research Research network |
| Drugs / interventions | cetuximab, immunotherapy |
| Locations | 1 site (Madrid) |
| Trial ID | NCT05117775 on ClinicalTrials.gov |
What this trial studies
This international, multicenter observational study analyzes electronic health records (EHRs) to understand the clinical characteristics and outcomes of patients with head and neck squamous cell carcinoma (HNSCC). By employing SAVANA's EHRead® technology, which utilizes Natural Language Processing and machine learning, the study aims to develop predictive models for identifying patients at high risk of recurrence and those who may benefit from immunotherapy. The study will focus on patients across all stages of HNSCC, providing insights into their real-world treatment outcomes and survival rates.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with head and neck squamous cell carcinoma.
Not a fit: Patients with less than 6 months of follow-up or those who do not meet the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for patients with head and neck cancer, improving survival rates and quality of life.
How similar studies have performed: Other studies utilizing similar data-driven approaches and predictive modeling have shown promise in improving patient outcomes, indicating potential success for this study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥18 years old. * Patients diagnosed with HNSCC * For selected exploratory analyses, patients diagnosed with nasopharynx, paranasal sinus, and salivary gland tumors. Exclusion Criteria: * Patients with follow-up of less than 6 months, except if deceased (any cause) in the 6 months after HNSCC diagnosis
Where this trial is running
Madrid
- Savan Research S.L — Madrid, Spain (Recruiting)
Study contacts
- Principal investigator: Miren Taberna — Medsavana S.L
- Study coordinator: Miren Taberna, MD,PhD
- Email: mtaberna@savanamed.com
- Phone: [+34] 910 69 69 02
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.